

## Gastric acid and GI disorders

Prof. Hein Yarzar Aung
Senior Consultant Physician
Clinical Director
North Okkalapa General Hospital

## Content

- 1. Physiology of gastric acid secretion
- 2. Phases of gastric acid secretion
- 3. Molecular control pathways
- 4. Disorders related to gastric acid secretion

- 1. Gastric Acid Composition
  - Hydrochloric acid (HCl) is secreted by <u>parietal cells</u> in the gastric glands
  - Maintains a <u>luminal pH of 1.5–3.5</u>
  - Functions
    - Protein denaturation
    - Activation of pepsinogen → pepsin
    - <u>Defense</u> against pathogens

- 2. Parietal Cell Function
  - Located in the <u>fundus and body</u> of the stomach
  - Acid is secreted via H<sup>+</sup>/K<sup>+</sup>-ATPase (proton pump) on the apical membrane

- 3. Stimulation of Acid Secretion
  - Neural
    - Vagus nerve (CN X) → Acetylcholine binds to M3 receptors → ↑ HCl
  - > Hormonal
    - Gastrin from G-cells (antrum)
    - Stimulates parietal cells directly
    - Stimulates enterochromaffin-like (ECL) cells → Histamine → H<sub>2</sub> receptors
  - Paracrine
    - Histamine from ECL cells binds to H₂ receptors → activates adenylate cyclase
       → ↑ cAMP → ↑ H⁺ secretion

- 4. Inhibition of Acid Secretion
  - Somatostatin from D cells (antrum) inhibits
    - G cells (↓ gastrin)
    - ECL cells (↓ histamine)
    - Parietal cells directly

- Prostaglandins (PGE2) inhibit acid by
  - Decreasing cAMP in parietal cells
  - Enhancing mucosal protection by ↑ mucus and bicarbonate

## 2. Phases of Gastric Acid Secretion

### Phases of Gastric Acid Secretion


Phase	Stimulus	% Total Acid	Mechanism
Cephalic	Sight, smell, thought of food	~30%	Vagal stimulation
Gastric	Food in stomach (distension, peptides)	~60%	Gastrin, vagal, local reflexes
Intestinal	Chyme in duodenum	~10%	Initially stimulates, then inhibits via secretin, CCK

## 3. Molecular control pathways of Gastric Acid Secretion

### Molecular control pathways of Gastric acid

- <u>cAMP Pathway</u> (Histamine)
  - Activates adenylate cyclase → ↑ cAMP → activates Protein Kinase A (PKA) → inserts H<sup>+</sup>/K<sup>+</sup> ATPase into membrane
- Ca<sup>2+</sup> Pathway (ACh, Gastrin)
  - Activates IP<sub>3</sub>/DAG pathway  $\rightarrow$  ↑ intracellular Ca<sup>2+</sup>  $\rightarrow$  stimulates acid secretion

#### Control of Gastric acid secretion



## Pharmacological Options for Acid Suppression

Class	Drug	Mechanism	Onset	Use
Antacids	MgOH₂, AlOH₃	Neutralize acid	Immediate	Symptomatic relief
Sucralfate	_	Protective mucosal barrier	_	Stress ulcers
Misoprostol	_	PGE₁ analog, increases mucus	_	NSAID-induced ulcers (pregnancy caution)
H2RAs	tidine	H2 receptor antagonist	Rapid (within 1 hr)	Mild GERD, adjunct to PPI
PPIs	prazole	Irreversible inhibition of H <sup>+</sup> /K <sup>+</sup> ATPase	1–2 hrs, max effect 3–4 days	GERD, PUD, ZES

### Molecular control pathways of Gastric acid

- Advanced molecular insights
  - > 1. H<sup>+</sup>/K<sup>+</sup>-ATPase (Proton Pump)
    - A P-type ATPase with  $\alpha$  and  $\beta$  subunits
    - Target of PPIs and Vonoprazan
  - 2. Proton Pump Trafficking
    - Resting parietal cells store pumps in tubulovesicles
    - Upon stimulation, vesicles fuse with the apical membrane → pump insertion →
      acid secretion
    - Actin, Rab11, and H<sup>+</sup>/K<sup>+</sup>-ATPase recycling are key in this vesicle trafficking

#### Control of Gastric acid secretion

- Vonoprazan: A Novel gastric acid suppressant,
  - ➤ A Potassium-Competitive Acid Blocker (P-CAB)
  - ▶ Directly blocks H<sup>+</sup>/K<sup>+</sup> ATPase at the K<sup>+</sup>-binding site, unlike PPIs which require acid activation

Feature	Vonoprazan	PPI
Target	K <sup>+</sup> site on proton pump	H <sup>+</sup> /K <sup>+</sup> -ATPase (sulfhydryl
		binding)
Activation	Active as given	Requires acid activation
рКа	~9.4 (stable)	Weak bases, degrade at neutral
		pH
Duration	~24 hours acid control	~12–16 hours
	Especially at night time	
pH Stability	Stable in acid	Unstable in acid

#### Control of Gastric acid secretion

- Vonoprazan: A Novel gastric acid suppressant
  - ➤ A Potassium-Competitive Acid Blocker (P-CAB)
  - ▶ Directly blocks H<sup>+</sup>/K<sup>+</sup> ATPase at the K<sup>+</sup>-binding site, unlike PPIs which require acid activation

Feature	Vonoprazan	PPI
Onset	1–2 hours	Depends on generation of PPI (average – hours and less rapid than Vonoprazan)
Acid suppression	More potent	Less potent
CYP metabolism	<u>Minimal</u>	Extensive (e.g., CYP2C19 polymorphisms affect PPIs)
Meal dependence	<u>No</u>	Yes

- 1. Gastroesophageal Reflux Disease (GERD)
  - Pathophysiology
    - Dysfunctional lower esophageal sphincter (LES) permits reflux of gastric contents
    - Chronic exposure causes esophagitis, Barrett's esophagus, and risk of adenocarcinoma

#### > Symptoms

- > Heartburn
- Regurgitation
- Dysphagia
- Chronic cough/laryngitis

- 2. Peptic Ulcer Disease (PUD)
  - **Causes** 
    - > H. pylori infection (80–90% of duodenal ulcers)
    - > NSAID use
    - Smoking
    - > Alcohol

- Pathophysiology
  - Disruption of mucosal defense by acid and pepsin

- 3. Zollinger–Ellison Syndrome (ZES)
  - Pathophysiology
    - ➤ Gastrin-secreting tumors (gastrinomas) → excessive acid → refractory ulcers

- Hypochlorhydria & Achlorhydria
  - > 1. Autoimmune Atrophic Gastritis & Pernicious Anemia
    - Pathophysiology
      - > Autoantibodies against parietal cells and intrinsic factor
      - ➤ Loss of acid → impaired B12 absorption
    - Complications
      - Megaloblastic anemia
      - Increased risk of gastric cancer

- Hypochlorhydria & Achlorhydria
- 2. Chronic PPI Use: Safety Considerations
  - Risks (with long-term use >1 year)
    - Malabsorption: B12, calcium, magnesium, iron
    - Enteric infections: C. difficile, Salmonella
    - Rebound hypersecretion
    - Renal complications, osteoporosis (debatable)

Disorder	Acid Status	Key Features
GERD	<b>↑</b>	Heartburn, regurgitation
PUD	<b>↑</b>	Epigastric pain, H. pylori
ZES	个个	Multiple ulcers, diarrhea
Atrophic Gastritis	<b>↓</b>	B12 deficiency
Chronic PPI Use	<b>↓</b>	Nutrient deficiencies

Take-home Message



# Gastric acid and GI disorders Take-home message

- 1. Gastric Acid: Essential Yet Potentially Harmful
  - Hydrochloric acid (HCl) is secreted by parietal cells in response to gastrin, histamine, and acetylcholine
  - It plays vital roles in
    - Protein digestion (via activation of pepsinogen to pepsin)
    - Defense against pathogens
    - Facilitating absorption of iron, calcium, and vitamin B12

# Gastric acid and GI disorders Take-home message

- 2. Dysregulation of Acid Secretion Is Central to Many GI Disorders
  - ➤ <u>Hypersecretion</u> (↑ Acid) Leads To
    - ➤ Gastroesophageal Reflux Disease (GERD)
    - Peptic Ulcer Disease (PUD)
    - Zollinger–Ellison Syndrome (ZES)

- ➤ <u>Hyposecretion</u> (↓ Acid) Associated With
  - Chronic PPI use
  - Autoimmune atrophic gastritis
  - Pernicious anemia

## Gastric acid and GI disorders Take-home message

- Balance of acid secretion and mucosal defense is crucial for GI health
- Helicobacter pylori and NSAIDs remain major preventable causes of PUD
- Gastric acid suppressing drugs must be used wisely
- Chronic acid suppression has real risks—evaluate indications regularly
- A novel gastric acid suppressing drug: Vonoprazan is now emerging with promising evidences from molecular level to clinical experiences



Thank you